These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 8994801)

  • 21. [Comparative characteristics of vanadium-containing compounds, possessing insulin-like effects].
    Golubev MA; Gorodetskiĭ VK; Anis'kina AP; Tochilkin AI; Beliaeva NF
    Vopr Med Khim; 2000; 46(2):155-61. PubMed ID: 10885036
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Protein tyrosine phosphatase 1B as a target for the treatment of impaired glucose tolerance and type II diabetes.
    Liu G; Trevillyan JM
    Curr Opin Investig Drugs; 2002 Nov; 3(11):1608-16. PubMed ID: 12476961
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Does inhibition of tyrosine phosphatase 1B protect from obesity and type 2 diabetes?].
    Ukkola O; Santaniemi M
    Duodecim; 2002; 118(18):1857-62. PubMed ID: 12422667
    [No Abstract]   [Full Text] [Related]  

  • 24. Mechanism of improving effect of losartan on insulin sensitivity of non-insulin-dependent diabetes mellitus rats.
    Wu Y; Ouyang JP; Zhou YF; Wu K; Zhao DH; Wen CY
    Sheng Li Xue Bao; 2004 Aug; 56(4):539-49. PubMed ID: 15322693
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of tumor necrosis factor-alpha on the phosphorylation of tyrosine kinase receptors is associated with dynamic alterations in specific protein-tyrosine phosphatases.
    Ahmad F; Goldstein BJ
    J Cell Biochem; 1997 Jan; 64(1):117-27. PubMed ID: 9015760
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Vanadium derivatives--a new source of antidiabetic drugs].
    Dănilă G; Lupaşcu D
    Rev Med Chir Soc Med Nat Iasi; 1999; 103(3-4):74-7. PubMed ID: 10756929
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Acute and chronic response to vanadium following two methods of streptozotocin-diabetes induction.
    Yao J; Battell ML; McNeill JH
    Can J Physiol Pharmacol; 1997 Feb; 75(2):83-90. PubMed ID: 9114928
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting protein tyrosine phosphatase to enhance insulin action for the potential treatment of diabetes.
    Kasibhatla B; Wos J; Peters KG
    Curr Opin Investig Drugs; 2007 Oct; 8(10):805-13. PubMed ID: 17907056
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prospects for inhibitors of protein tyrosine phosphatase 1B as antidiabetic drugs.
    Hooft van Huijsduijnen R; Sauer WH; Bombrun A; Swinnen D
    J Med Chem; 2004 Aug; 47(17):4142-6. PubMed ID: 15293983
    [No Abstract]   [Full Text] [Related]  

  • 30. Inhibition of the protein tyrosine phosphatase PTP1B: potential therapy for obesity, insulin resistance and type-2 diabetes mellitus.
    Koren S; Fantus IG
    Best Pract Res Clin Endocrinol Metab; 2007 Dec; 21(4):621-40. PubMed ID: 18054739
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Modern approaches to pharmacotherapy of diabetes mellitus type II].
    Kovel'man IR; Tochilkin AI; Beliaeva NF; Gorodetskiĭ VK; Kniazhev VA; Tkachenko SB; Semenov LL; Semenova NV
    Vopr Med Khim; 2002; 48(4):337-52. PubMed ID: 12506608
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synthesis, activity and molecular modeling of a new series of chromones as low molecular weight protein tyrosine phosphatase inhibitors.
    Forghieri M; Laggner C; Paoli P; Langer T; Manao G; Camici G; Bondioli L; Prati F; Costantino L
    Bioorg Med Chem; 2009 Apr; 17(7):2658-72. PubMed ID: 19297174
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Molecular targets for new drug discovery to treat type 2 diabetes and obesity].
    Bastarrachea RA; Montero JC; Saavedra-Gajardo I; Cerda-Flores R; Machado-Domínguez A; Comuzzie AG
    Rev Med Chil; 2008 Jan; 136(1):107-17. PubMed ID: 18483661
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [New outlooks in the treatment of diabetes].
    Salamanca-Gómez F
    Gac Med Mex; 1999; 135(4):441-2. PubMed ID: 10491904
    [No Abstract]   [Full Text] [Related]  

  • 35. Evidence for the distinct vanadyl(+4)-dependent activating system for manifesting insulin-like effects.
    Li J; Elberg G; Crans DC; Shechter Y
    Biochemistry; 1996 Jun; 35(25):8314-8. PubMed ID: 8679588
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synthesis, in vitro and computational studies of protein tyrosine phosphatase 1B inhibition of a small library of 2-arylsulfonylaminobenzothiazoles with antihyperglycemic activity.
    Navarrete-Vazquez G; Paoli P; León-Rivera I; Villalobos-Molina R; Medina-Franco JL; Ortiz-Andrade R; Estrada-Soto S; Camici G; Diaz-Coutiño D; Gallardo-Ortiz I; Martinez-Mayorga K; Moreno-Díaz H
    Bioorg Med Chem; 2009 May; 17(9):3332-41. PubMed ID: 19362487
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hypoglycemic effect of Astragalus polysaccharide and its effect on PTP1B.
    Wu Y; Ou-Yang JP; Wu K; Wang Y; Zhou YF; Wen CY
    Acta Pharmacol Sin; 2005 Mar; 26(3):345-52. PubMed ID: 15715932
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vanadium compounds for the treatment of human diabetes mellitus: A scientific curiosity? A review of thirty years of research.
    Domingo JL; Gómez M
    Food Chem Toxicol; 2016 Sep; 95():137-41. PubMed ID: 27417449
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vanadium activates or inhibits receptor and non-receptor protein tyrosine kinases in cell-free experiments, depending on its oxidation state. Possible role of endogenous vanadium in controlling cellular protein tyrosine kinase activity.
    Elberg G; Li J; Shechter Y
    J Biol Chem; 1994 Apr; 269(13):9521-7. PubMed ID: 8144537
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novel protein tyrosine phosphatase 1B inhibitors: interaction requirements for improved intracellular efficacy in type 2 diabetes mellitus and obesity control.
    Popov D
    Biochem Biophys Res Commun; 2011 Jul; 410(3):377-81. PubMed ID: 21683066
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.